

Company name : KYORIN Holdings, Inc.  
Representative Director, President : Minoru Hogawa  
Securities Code : 4569, TSE 1st Sec.

**Approval received for KIPRES<sup>®</sup> OD Tablets 10mg,  
a treatment for bronchial asthma and allergic rhinitis**

TOKYO, Japan (August 17, 2015) — Kyorin Pharmaceutical Co., Ltd. (“Kyorin”) (Head office: Chiyoda-ku, Tokyo, President: Mitsutomo Miyashita), a wholly owned subsidiary of KYORIN Holdings, Inc., announced that a leukotriene receptor antagonist / bronchial asthma and allergic rhinitis treatment drug of “KIPRES<sup>®</sup> OD Tablets 10mg” (INN: montelukast sodium), received marketing authorization from the Ministry of Health, Labour and Welfare (“MHLW”) on August 17.

The leukotriene receptor antagonist is selective for the Cys LT<sub>1</sub> receptors developed by Merck & Co., Inc. (Kenilworth, N.J., U.S.A.). In August 2001, Kyorin Pharmaceutical launched Kipres<sup>®</sup> Tablets (10 mg) for adults and Kipres<sup>®</sup> Chewable Tablets (5 mg) for children ages 6 and up. Since then, the company has launched Kipres<sup>®</sup> Fine Granules (4 mg) for children between the ages of 1 and 6 and Kipres<sup>®</sup> Tablets (5 mg) for adults in an effort to extensively improve and expand its product lineup. These drugs have also obtained indications for allergic rhinitis (in adults), and have contributed to the treatment of bronchial asthma and allergic rhinitis.

Recently, Kipres<sup>®</sup> OD Tablets (10 mg) gained approval to be manufactured and marketed. Designed to quickly disintegrate in the mouth, the orally disintegrating tablets can be taken without water and are easily ingested orally by the elderly and patients who have grown less capable of swallowing conventional solid formulations. We believe the tablets offer proper and desirable choices of dosage forms to more patients, and will lead to improvements in medication compliance.

Moving forward, Kyorin Pharmaceutical will continue supporting the treatment of bronchial asthma and allergic rhinitis with the addition of Kipres<sup>®</sup> OD Tablets (10 mg) to its existing lineup of dosage forms.

(Product information)

1. Brand name : KIPRES<sup>®</sup> OD Tablets 10mg

2. Active ingredient : Montelukast Sodium

3. Indications : Bronchial Asthma, Allergic Rhinitis

4. Dosage and Administration :

< Bronchial Asthma > Recommended dosage for adults is usually 10mg as montelukast orally administered once daily before bedtime.

< Allergic Rhinitis > Recommended dosage for adults is usually 5-10mg as montelukast orally administered once daily before bedtime.

5. NHI Price : Not yet listed